Skip to Content
You are currently on the new version of our website. Access the old version .
ToxinsToxins
  • Review
  • Open Access

17 February 2023

A Review on Genotoxic and Genoprotective Effects of Biologically Active Compounds of Animal Origin

and
1
Department of Medical Biochemistry, Faculty of Medicine, University of Latvia, 1004 Riga, Latvia
2
Genetics and Bioinformatics, Institute of Biology, University of Latvia, 1004 Riga, Latvia
3
Mutagenesis Unit, Institute for Medical Research and Occupational Health, 10000 Zagreb, Croatia
*
Authors to whom correspondence should be addressed.

Abstract

Envenomation by animal venoms remains a serious medical and social problem, especially in tropical countries. On the other hand, animal venoms are widely used as a source of biologically active compounds for the development of novel drugs. Numerous derivatives of animal venoms are already used in clinical practice. When analysing the mechanisms of action of animal venoms, attention is usually focused on the main target of the venom’s enzymes and peptides such as neurotoxic, cytotoxic or haemorrhagic effects. In the present review, we would like to draw attention to the “hidden” effects of animal venoms and their derivatives in regard to DNA damage and/or protection against DNA damage. Alkaloids and terpenoids isolated from sponges such as avarol, ingenamine G or variolin B manifest the capability to bind DNA in vitro and produce DNA breaks. Trabectidin, isolated from a sea squirt, also binds and damages DNA. A similar action is possible for peptides isolated from bee and wasp venoms such as mastoparan, melectin and melittin. However, DNA lesions produced by the crude venoms of jellyfish, scorpions, spiders and snakes arise as a consequence of cell membrane damage and the subsequent oxidative stress, whereas certain animal venoms or their components produce a genoprotective effect. Current research data point to the possibility of using animal venoms and their components in the development of various potential therapeutic agents; however, before their possible clinical use the route of injection, molecular target, mechanism of action, exact dosage, possible side effects and other fundamental parameters should be further investigated.
Key Contribution:
Summarized genotoxic and genoprotective effects of biologically active compounds of animal origin, mainly venoms and their derivatives, will contribute to a better understanding of their impact on DNA molecules in regard to their possible therapeutic applications.

1. Introduction

Pharmaceuticals derived from animals continuously make a major contribution to health in terms of prevention and treatment of many diseases [1,2,3,4]. Animal venoms and their components, such as those from snakes, scorpions, spiders, bees, wasps, snails, toads, frogs, lizards and sea anemones have long been used in scientific research and are the basis of many products and drugs that are of great use in medicine today [5,6,7,8,9,10,11,12]. Crude venoms are complex bioactive chemicals rich in proteins and peptides with diverse pharmacological actions that are often protease-resistant due to their disulphide-rich structures. For example, in spider venoms the disulphide bridges form “cysteine knots”, where three bridges stabilize antiparallel beta sheets, drastically increasing the stability of the protein [13]. The components of venoms are specific, stable, potent and have the ability to modify molecular targets, thus making good therapeutic candidates. Animal venoms have been used as a traditional medicine to treat a variety of conditions, including arthritis, rheumatism and chronic pain as well as autoimmune, cardiovascular and skin diseases [3,6,14,15,16,17]. Moreover, one of the most promising fields in venom research from the therapeutic aspect is their use in anticancer research. This is driven by the resistance to chemotherapeutics by cancerous cells that is making cancer treatment more complicated, hence, animal venoms have emerged as an alternative strategy for anticancer therapeutics and could also impact the costs related to cancer treatment [15,18,19,20,21,22,23]. The anticancer activities of animal venoms include the inhibition of the proliferation of cancer cells, their invasion, cell cycle arrest, induction of apoptosis or necrosis and the identification of the involved signalling pathways [14,15,24].
Although there are numerous animal venoms that often show good results towards cancerous cells, there are always open questions regarding their potential toxicity towards normal non-target cells and tissues, making this kind of toxicity one of the greatest obstacles for the possibility of an actual remedy [4,14,25,26,27]. Therefore, the possible genotoxic effects of chemical compounds used as medical remedies are intensively studied. There is a vast body of literature concerning both natural and synthetic compounds [28,29]. Much less attention is paid to the genotoxic effects of animal venoms and other compounds of animal origin, although animal venoms per se are in the focus of interest of numerous researchers [4]. However, genotoxic effects can be produced by these compounds due to envenomation or as a side effect of medical remedies.
In this integrative review, we shall try to summarize the accessible data on genotoxic and/or genoprotective activities of the venoms and their components. Data will be reviewed following biological systematics. We conducted a search to identify relevant papers using scientific databases, including PubMed (www.pubmed.com (accessed on 1 February 2023)), Web of Knowledge (www.webofknowledge.com (accessed on 1 February 2023)) and Scopus (www.scopus.com (accessed on 1 February 2023)). The keywords comprised the name of the taxon, the word “venom” and the sought effect, for example “snake venom and DNA damage”, “snake venom and comet assay”. If the individual DNA-damaging components of the venom were revealed, the search was repeated with the name of the compound, for example “trabectidin and DNA damage”, “trabectidin and DNA binding” and “trabectidin and comet assay”, etc. The titles and abstracts were assessed to consider the articles for inclusion in the review, with sixty papers found. We did not apply any restriction concerning the publication language, country or dates of publication. Other relevant original and review papers were also identified from the reference lists of papers found in the search and those papers have been included in the present review and summarized in Table 1. The papers describing comet assay experiments were included if at least 50 cells were analysed per experimental point and several concentrations of the active compound were compared with the negative and positive controls (Figure 1). Papers on the topic first appeared in 2002 and the number of publications has increased since 2010, whereas in the last few years there were four publications yearly. There are one or two publications about one species, with the exception for honeybees where thirteen papers were published.
Table 1. Genotoxic and genoprotective effects of animal venom components with pharmacological action.
Figure 1. Schematic presentation of the organization of experiments aimed toward the study of the genotoxic effects of venoms.

3. Conclusions and Future Perspectives

The overview of the above data indicates that data are fragmentary; venoms of animals from several taxons were not tested for genotoxicity. There are no data about fish venoms, molluscan venoms or venoms of myriapods, etc. Data on snakes and amphibians are also fragmentary. However, the presented data clearly indicate the importance of such studies. From the point of view of the mechanisms of action, only some compounds isolated from marine invertebrates such as avarol and trabectidin are DNA binders, thus DNA damage is produced by the compounds themselves. Venoms of other animals act indirectly by producing membrane damage or inducing oxidative stress; consequently, DNA damage arises as a secondary effect (Figure 3).
Figure 3. Possible mechanism of genotoxic action of the venom enzymes.
Due to venoms’ non-specific toxicity, their therapeutic potential cannot be achieved without a proper delivery vehicle. This could be overcome by nanoparticles that possess the ability to safely deliver a significant amount of venom and/or their components intravenously to target and kill tumour cells [92,93]. Another possibility is a combination drug therapy using the existing chemotherapeutic agents with venom components, which could be useful from the aspect of minimizing concentrations of standard chemotherapeutic drugs during chemotherapy [18,19,94,95]. Since it can be suggested that the future prospects of cancer treatment could lie in combination therapy, it should also be noted that such combinations might lead to the development of toxicities, which need to be evaluated along with the observed anticancer or other therapeutic potentials. Current research data point to the possibility of using animal venoms in the development of antitumour drugs as well as other potential therapeutic agents; several FDA-approved drugs derived from venom peptides or proteins already exist [3]. However, before its possible clinical use, the route of injection, molecular targets, mechanisms of action, exact dosage, possible side effects and other fundamental parameters should be further investigated. Moreover, making these molecules applicable requires extensive preclinical trials, with some applications also demanding clinical trials [96].
Moreover, several new techniques, including bioinformatics tools and in silico analysis, can support the development of new therapeutic agents based on animal biodiversity aimed at large-scale prediction of erythrocyte lysis induced by peptides. Hence, many online databases filled with peptide sequences and their biological metadata have paved the way toward haemolysis prediction using user-friendly, fast-access machine-learning-driven programs. Although the development of such predictive approaches to peptide toxicity has only just started, their contributions demonstrate the large potential for peptide science and computer-aided drug design in the identification of selective, non-toxic peptide therapeutics. Nevertheless, these new approaches must consider predicting the balance between toxicity and therapeutic effect. Hence, the future design of peptide pharmaceuticals should include the interplay between computational, in vitro and in vivo approaches [97,98,99,100].
Due to the enormous venom diversity, further research is needed, and our knowledge in this regard is still limited. For the application of biologically active compounds of animal origin as pharmacological tools and medications, the development of innovative approaches and best practices for target identification will be critical.

Author Contributions

Conceptualization, N.S.; methodology, N.S. and G.G.; writing—original draft preparation, N.S. and G.G.; writing—review and editing, N.S. and G.G.; visualization, N.S.; supervision, N.S. and G.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

This work was supported by affiliated institutions and the European Cooperation in Science and Technology (CA COST Action CA19144—European Venom Network (EUVEN)). The authors would like to thank E. Leonova (University of Latvia) for preparation of figures and M. Herman (Institute for Medical Research and Occupational Health) for English language corrections.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. McDermott, A. News Feature: Venom Back in Vogue as a Wellspring for Drug Candidates. Proc. Natl. Acad. Sci. USA 2020, 117, 10100–10104. [Google Scholar] [CrossRef]
  2. Holford, M.; Daly, M.; King, G.F.; Norton, R.S. Venoms to the Rescue. Science 2018, 361, 842–844. [Google Scholar] [CrossRef]
  3. King, G.F. Venoms as a Platform for Human Drugs: Translating Toxins into Therapeutics. Expert Opin. Biol. Ther. 2011, 11, 1469–1484. [Google Scholar] [CrossRef]
  4. von Reumont, B.M.; Anderluh, G.; Antunes, A.; Ayvazyan, N.; Beis, D.; Caliskan, F.; Crnković, A.; Damm, M.; Dutertre, S.; Ellgaard, L.; et al. Modern Venomics-Current Insights, Novel Methods, and Future Perspectives in Biological and Applied Animal Venom Research. Gigascience 2022, 11, giac048. [Google Scholar] [CrossRef]
  5. Abd El-Aziz, T.M.; Garcia Soares, A.; Stockand, J.D. Snake Venoms in Drug Discovery: Valuable Therapeutic Tools for Life Saving. Toxins 2019, 11, 564. [Google Scholar] [CrossRef]
  6. Son, D.J.; Lee, J.W.; Lee, Y.H.; Song, H.S.; Lee, C.K.; Hong, J.T. Therapeutic Application of Anti-Arthritis, Pain-Releasing, and Anti-Cancer Effects of Bee Venom and Its Constituent Compounds. Pharmacol. Ther. 2007, 115, 246–270. [Google Scholar] [CrossRef]
  7. Kalita, B.; Saviola, A.J.; Mukherjee, A.K. From Venom to Drugs: A Review and Critical Analysis of Indian Snake Venom Toxins Envisaged as Anticancer Drug Prototypes. Drug Discov. Today 2021, 26, 993–1005. [Google Scholar] [CrossRef]
  8. Qi, J.; Zulfiker, A.H.M.; Li, C.; Good, D.; Wei, M.Q. The Development of Toad Toxins as Potential Therapeutic Agents. Toxins 2018, 10, 336. [Google Scholar] [CrossRef]
  9. Saez, N.J.; Senff, S.; Jensen, J.E.; Er, S.Y.; Herzig, V.; Rash, L.D.; King, G.F. Spider-Venom Peptides as Therapeutics. Toxins 2010, 2, 2851–2871. [Google Scholar] [CrossRef]
  10. Muttenthaler, M.; King, G.F.; Adams, D.J.; Alewood, P.F. Trends in Peptide Drug Discovery. Nat. Rev. Drug Discov. 2021, 20, 309–325. [Google Scholar] [CrossRef]
  11. Harvey, A. From Demons to Darlings: Drugs from Venoms. Drug Discov. Today 1998, 3, 531–532. [Google Scholar] [CrossRef]
  12. Gajski, G.; Čimbora-Zovko, T.; Osmak, M.; Garaj-Vrhovac, V. Bee Venom and Melittin Are Cytotoxic against Different Types of Tumor and Non-Tumor Cell Lines In Vitro. In Advancements in Cancer Research; Viktorsson, K., Ed.; Nova Science Publishers, Inc.: Hauppauge, NY, USA, 2012; pp. 163–178. ISBN 978-1-61470-252-8. [Google Scholar]
  13. Herzig, V.; King, G.F. The Cystine Knot Is Responsible for the Exceptional Stability of the Insecticidal Spider Toxin ω-Hexatoxin-Hv1a. Toxins 2015, 7, 4366–4380. [Google Scholar] [CrossRef]
  14. Gajski, G.; Garaj-Vrhovac, V. Melittin: A Lytic Peptide with Anticancer Properties. Environ. Toxicol. Pharmacol. 2013, 36, 697–705. [Google Scholar] [CrossRef]
  15. Chatterjee, B. Animal Venoms Have Potential to Treat Cancer. Curr. Top. Med. Chem. 2018, 18, 2555–2566. [Google Scholar] [CrossRef]
  16. Lewis, R.J.; Garcia, M.L. Therapeutic Potential of Venom Peptides. Nat. Rev. Drug Discov. 2003, 2, 790–802. [Google Scholar] [CrossRef]
  17. Greener, M. The next Generation of Venom-based Drugs. Prescriber 2020, 31, 28–32. [Google Scholar] [CrossRef]
  18. Gajski, G.; Čimbora-Zovko, T.; Rak, S.; Rožman, M.; Osmak, M.; Garaj-Vrhovac, V. Combined Antitumor Effects of Bee Venom and Cisplatin on Human Cervical and Laryngeal Carcinoma Cells and Their Drug Resistant Sublines. J. Appl. Toxicol. 2014, 34, 1332–1341. [Google Scholar] [CrossRef]
  19. Gajski, G.; Čimbora-Zovko, T.; Rak, S.; Osmak, M.; Garaj-Vrhovac, V. Antitumour Action on Human Glioblastoma A1235 Cells through Cooperation of Bee Venom and Cisplatin. Cytotechnology 2016, 68, 1197–1205. [Google Scholar] [CrossRef]
  20. Roy, A.; Bharadvaja, N. Venom-Derived Bioactive Compounds as Potential Anticancer Agents: A Review. Int. J. Pept. Res. Ther. 2021, 27, 129–147. [Google Scholar] [CrossRef]
  21. Chaisakul, J.; Hodgson, W.C.; Kuruppu, S.; Prasongsook, N. Effects of Animal Venoms and Toxins on Hallmarks of Cancer. J. Cancer 2016, 7, 1571–1578. [Google Scholar] [CrossRef]
  22. Viegas, S.; Ladeira, C.; Costa-Veiga, A.; Perelman, J.; Gajski, G. Forgotten Public Health Impacts of Cancer—An Overview. Arch. Ind. Hyg. Toxicol. 2017, 68, 287–297. [Google Scholar] [CrossRef] [PubMed]
  23. Norouzi, P.; Mirmohammadi, M.; Houshdar Tehrani, M.H. Anticancer Peptides Mechanisms, Simple and Complex. Chem. Biol. Interact. 2022, 368, 110194. [Google Scholar] [CrossRef] [PubMed]
  24. Oršolić, N. Bee Venom in Cancer Therapy. Cancer Metastasis Rev. 2012, 31, 173–194. [Google Scholar] [CrossRef] [PubMed]
  25. Gajski, G.; Domijan, A.-M.; Žegura, B.; Štern, A.; Gerić, M.; Novak Jovanović, I.; Vrhovac, I.; Madunić, J.; Breljak, D.; Filipič, M.; et al. Melittin Induced Cytogenetic Damage, Oxidative Stress and Changes in Gene Expression in Human Peripheral Blood Lymphocytes. Toxicon 2016, 110, 56–67. [Google Scholar] [CrossRef]
  26. Gajski, G.; Garaj-Vrhovac, V. Bee Venom Induced Cytogenetic Damage and Decreased Cell Viability in Human White Blood Cells after Treatment in Vitro: A Multi-Biomarker Approach. Environ. Toxicol. Pharmacol. 2011, 32, 201–211. [Google Scholar] [CrossRef]
  27. Garaj-Vrhovac, V.; Gajski, G. Evaluation of the Cytogenetic Status of Human Lymphocytes after Exposure to a High Concentration of Bee Venom in Vitro. Arch. Hig. Rada Toksikol. 2009, 60, 27–34. [Google Scholar] [CrossRef]
  28. Sjakste, N.; Djelić, N.; Dzintare, M.; Živković, L. DNA-BINDING and DNA-Protecting Activities of Small Natural Organic Molecules and Food Extracts. Chem. Biol. Interact. 2020, 323, 109030. [Google Scholar] [CrossRef]
  29. Muhamedejevs, R.; Živković, L.; Dzintare, M.; Sjakste, N. DNA-Binding Activities of Compounds Acting as Enzyme Inhibitors, Ion Channel Blockers and Receptor Binders. Chem. Biol. Interact. 2021, 348, 109638. [Google Scholar] [CrossRef]
  30. Sladic, D.; Gasic, M. Reactivity and Biological Activity of the Marine Sesquiterpene Hydroquinone Avarol and Related Compounds from Sponges of the Order Dictyoceratida. Molecules 2006, 11, 1–33. [Google Scholar] [CrossRef]
  31. Pejin, B.; Iodice, C.; Kojic, V.; Jakimov, D.; Lazovic, M.; Tommonaro, G. In Vitro Evaluation of Cytotoxic and Mutagenic Activity of Avarol. Nat. Prod. Res. 2016, 30, 1293–1296. [Google Scholar] [CrossRef]
  32. Su, J.-H.; Chang, W.-B.; Chen, H.-M.; El-Shazly, M.; Du, Y.-C.; Kung, T.-H.; Chen, Y.-C.; Sung, P.-J.; Ho, Y.-S.; Kuo, F.-W.; et al. 10-Acetylirciformonin B, A Sponge Furanoterpenoid, Induces DNA Damage and Apoptosis in Leukemia Cells. Molecules 2012, 17, 11839–11848. [Google Scholar] [CrossRef] [PubMed]
  33. Cavalcanti, B.C.; Sombra, C.M.L.; de Oliveira, J.H.H.L.; de Berlinck, R.G.S.; de Moraes, M.O.; Pessoa, C. Cytotoxicity and Genotoxicity of Ingenamine G Isolated from the Brazilian Marine Sponge Pachychalina Alcaloidifera. Comp. Biochem. Physiol. Part C: Toxicol. Pharmacol. 2008, 147, 409–415. [Google Scholar] [CrossRef] [PubMed]
  34. Canals, A.; Arribas-Bosacoma, R.; Albericio, F.; Álvarez, M.; Aymamí, J.; Coll, M. Intercalative DNA Binding of the Marine Anticancer Drug Variolin B. Sci. Rep. 2017, 7, 39680. [Google Scholar] [CrossRef] [PubMed]
  35. Dave, J.R.; Williams, A.J.; Moffett, J.R.; Koenig, M.L.; Tortella, F.C. Studies on Neuronal Apoptosis in Primary Forebrain Cultures: Neuroprotective/Anti-Apoptotic Action of NR2B NMDA Antagonists. Neurotox. Res. 2003, 5, 255–264. [Google Scholar] [CrossRef] [PubMed]
  36. de Souza, A.H.; da Rosa, L.G.; Uliano, M.R.; da Silva Prado, L.; Ferraz, A.G.; Conter, L.U.; Grivicich, I.; Dallegrave, E.; Gomez, M.V.; Picada, J.N. Evaluation of DNA Damage in Spinal Cord and Mutagenic Effect of a Phα1β Recombinant Toxin with Analgesic Properties from the Phoneutria Nigriventer Spider. Basic Clin. Pharmacol. Toxicol. 2019, 124, 615–620. [Google Scholar] [CrossRef]
  37. de Santana, C.J.C.; Pires Júnior, O.R.; Fontes, W.; Palma, M.S.; Castro, M.S. Mastoparans: A Group of Multifunctional α-Helical Peptides With Promising Therapeutic Properties. Front. Mol. Biosci. 2022, 9, 331. [Google Scholar] [CrossRef]
  38. Liang, X.; Yan, J.; Lu, Y.; Liu, S.; Chai, X. The Antimicrobial Peptide Melectin Shows Both Antimicrobial and Antitumor Activity via Membrane Interference and DNA Binding. Drug Des. Devel. Ther. 2021, 15, 1261–1273. [Google Scholar] [CrossRef]
  39. Gajski, G.; Domijan, A.-M.; Garaj-Vrhovac, V. Alterations of GSH and MDA Levels and Their Association with Bee Venom-Induced DNA Damage in Human Peripheral Blood Leukocytes. Environ. Mol. Mutagen. 2012, 53, 469–477. [Google Scholar] [CrossRef]
  40. Gajski, G.; Garaj-Vrhovac, V. Genotoxic Potential of Bee Venom (Apis Mellifera) on Human Peripheral Blood Lymphocytes in Vitro Using Single Cell Gel Electrophoresis Assay. J. Environ. Sci. Health A Tox Hazard Subst. Environ. Eng. 2008, 43, 1279–1287. [Google Scholar] [CrossRef]
  41. Gajski, G.; Garaj-Vrhovac, V. Increased Frequency of Sister Chromatid Exchanges and Decrease in Cell Viability and Proliferation Kinetics in Human Peripheral Blood Lymphocytes after In Vitro Exposure to Whole Bee Venom. J. Environ. Sci. Health A Tox Hazard Subst. Environ. Eng. 2010, 45, 1654–1659. [Google Scholar] [CrossRef]
  42. Malyarenko, O.S.; Malyarenko, T.V.; Kicha, A.A.; Ivanchina, N.V.; Ermakova, S.P. Effects of Polar Steroids from the Starfish Patiria (=Asterina) Pectinifera in Combination with X-Ray Radiation on Colony Formation and Apoptosis Induction of Human Colorectal Carcinoma Cells. Molecules 2019, 24, 3154. [Google Scholar] [CrossRef]
  43. Guirouilh-Barbat, J.; Redon, C.; Pommier, Y. Transcription-Coupled DNA Double-Strand Breaks Are Mediated via the Nucleotide Excision Repair and the Mre11-Rad50-Nbs1 Complex. Mol. Biol. Cell 2008, 19, 3969–3981. [Google Scholar] [CrossRef] [PubMed]
  44. Wang, Y.-Z.; Wang, Y.-M.; Pan, X.; Chi, C.-F.; Wang, B. Antioxidant Mechanisms of the Oligopeptides (FWKVV and FMPLH) from Muscle Hydrolysate of Miiuy Croaker against Oxidative Damage of HUVECs. Oxid. Med. Cell. Longev. 2021, 2021, 9987844. [Google Scholar] [CrossRef] [PubMed]
  45. Bhattacharjee, P.; Giri, B.; Gomes, A. Apoptogenic Activity and Toxicity Studies of a Cytotoxic Protein (BMP1) from the Aqueous Extract of Common Indian Toad (Bufo Melanostictus Schneider) Skin. Toxicon 2011, 57, 225–236. [Google Scholar] [CrossRef] [PubMed]
  46. da Machado, K.C.; de Sousa, L.Q.; Lima, D.J.B.; Soares, B.M.; Cavalcanti, B.C.; Maranhão, S.S.; Noronha, J.; de Jesus Rodrigues, D.; Militão, G.C.G.; Chaves, M.H.; et al. Marinobufagin, a Molecule from Poisonous Frogs, Causes Biochemical, Morphological and Cell Cycle Changes in Human Neoplasms and Vegetal Cells. Toxicol. Lett. 2018, 285, 121–131. [Google Scholar] [CrossRef] [PubMed]
  47. Pastor, N.; Domínguez, I.; Mateos, S.; Cortés, F. A Comparative Study of Genotoxic Effects of Anti-Topoisomerase II Drugs ICRF-193 and Bufalin in Chinese Hamster Ovary Cells. Mutat. Res. 2002, 515, 171–180. [Google Scholar] [CrossRef]
  48. Doumanov, J.; Mladenova, K.; Topouzova-Hristova, T.; Stoitsova, S.; Petrova, S. Effects of Vipoxin and Its Components on HepG2 Cells. Toxicon 2015, 94, 36–44. [Google Scholar] [CrossRef]
  49. Machado, A.R.T.; Aissa, A.F.; Ribeiro, D.L.; Costa, T.R.; Ferreira Jr., R.S.; Sampaio, S.V.; Antunes, L.M.G. Cytotoxic, Genotoxic, and Oxidative Stress-Inducing Effect of an l-Amino Acid Oxidase Isolated from Bothrops Jararacussu Venom in a Co-Culture Model of HepG2 and HUVEC Cells. Int. J. Biol. Macromol. 2019, 127, 425–432. [Google Scholar] [CrossRef]
  50. Machado, A.R.T.; Aissa, A.F.; Ribeiro, D.L.; Hernandes, L.C.; Machado, C.S.; Bianchi, M.L.P.; Sampaio, S.V.; Antunes, L.M.G. The Toxin BjussuLAAO-II Induces Oxidative Stress and DNA Damage, Upregulates the Inflammatory Cytokine Genes TNF and IL6, and Downregulates the Apoptotic-Related Genes BAX, BCL2 and RELA in Human Caco-2 Cells. Int. J. Biol. Macromol. 2018, 109, 212–219. [Google Scholar] [CrossRef]
  51. de Moura Leão, M.F.; Duarte, J.A.; Sauzen, P.D.; da Piccoli, J.C.E.; de Oliveira, L.F.S.; Machado, M.M. Cytotoxic and Genotoxic Effects of Antihypertensives Distributed in Brazil by Social Programs: Are They Safe? Environ. Toxicol. Pharmacol. 2018, 63, 1–5. [Google Scholar] [CrossRef]
  52. Marcussi, S.; Santos, P.R.S.; Menaldo, D.L.; Silveira, L.B.; Santos-Filho, N.A.; Mazzi, M.V.; da Silva, S.L.; Stábeli, R.G.; Antunes, L.M.G.; Soares, A.M. Evaluation of the Genotoxicity of Crotalus Durissus Terrificus Snake Venom and Its Isolated Toxins on Human Lymphocytes. Mutat. Res. 2011, 724, 59–63. [Google Scholar] [CrossRef] [PubMed]
  53. Ayed, Y.; Boussabbeh, M.; Zakhama, W.; Bouaziz, C.; Abid, S.; Bacha, H. Induction of Cytotoxicity of Pelagia Noctiluca Venom Causes Reactive Oxygen Species Generation, Lipid Peroxydation Induction and DNA Damage in Human Colon Cancer Cells. Lipids Health Dis. 2011, 10, 232. [Google Scholar] [CrossRef] [PubMed]
  54. Ayed, Y.; Bouaziz, C.; Brahmi, D.; Zaid, C.; Abid, S.; Bacha, H. Cell Death in Relation to DNA Damage after Exposure to the Jellyfish Pelagia Noctiluca Nematocysts. Environ. Toxicol. 2014, 29, 337–344. [Google Scholar] [CrossRef] [PubMed]
  55. Anjum, K.; Abbas, S.Q.; Shah, S.A.A.; Akhter, N.; Batool, S.; Hassan, S.S.U. Marine Sponges as a Drug Treasure. Biomol. Ther. 2016, 24, 347–362. [Google Scholar] [CrossRef]
  56. Varijakzhan, D.; Loh, J.-Y.; Yap, W.-S.; Yusoff, K.; Seboussi, R.; Lim, S.-H.E.; Lai, K.-S.; Chong, C.-M. Bioactive Compounds from Marine Sponges: Fundamentals and Applications. Mar. Drugs 2021, 19, 246. [Google Scholar] [CrossRef]
  57. Talevska, A.; Pejin, B.; Kojic, V.; Beric, T.; Stankovic, S. A Contribution to Pharmaceutical Biology of Freshwater Sponges. Nat. Prod. Res. 2018, 32, 568–571. [Google Scholar] [CrossRef]
  58. Ferretti, C.; Marengo, B.; De Ciucis, C.; Nitti, M.; Pronzato, M.; Marinari, U.; Pronzato, R.; Manconi, R.; Domenicotti, C. Effects of Agelas Oroides and Petrosia Ficiformis Crude Extracts on Human Neuroblastoma Cell Survival. Int. J. Oncol. 2007, 30, 161–169. [Google Scholar] [CrossRef]
  59. Aiub, C.; Giannerini, A.; Ferreira, F.; Mazzei, J.; Stankevicins, L.; Lobo-Hajdu, G.; Guimarães, P.; Hajdu, E.; Felzenszwalb, I. Genotoxic Evaluation of Extracts from Aplysina Fulva, a Brazilian Marine Sponge. Mutat. Res. 2006, 611, 34–41. [Google Scholar] [CrossRef]
  60. Vujčić, M.T.; Tufegdžić, S.; Novaković, I.; Djikanović, D.; Gašić, M.J.; Sladić, D. Studies on the Interactions of Bioactive Quinone Avarone and Its Methylamino Derivatives with Calf Thymus DNA. Int. J. Biol. Macromol. 2013, 62, 405–410. [Google Scholar] [CrossRef]
  61. Patiño Cano, L.P.; Bartolotta, S.A.; Casanova, N.A.; Siless, G.E.; Portmann, E.; Schejter, L.; Palermo, J.A.; Carballo, M.A. Isolation of Acetylated Bile Acids from the Sponge Siphonochalina Fortis and DNA Damage Evaluation by the Comet Assay. Steroids 2013, 78, 982–986. [Google Scholar] [CrossRef]
  62. D’Ambrosio, M.; Ramos, Í.; Martins, C.; Costa, P.M. An Investigation into the Toxicity of Tissue Extracts from Two Distinct Marine Polychaeta. Toxicon X 2022, 14, 100116. [Google Scholar] [CrossRef] [PubMed]
  63. Jin, A.-H.; Muttenthaler, M.; Dutertre, S.; Himaya, S.W.A.; Kaas, Q.; Craik, D.J.; Lewis, R.J.; Alewood, P.F. Conotoxins: Chemistry and Biology. Chem. Rev. 2019, 119, 11510–11549. [Google Scholar] [CrossRef] [PubMed]
  64. Escoubas, P.; Diochot, S.; Corzo, G. Structure and Pharmacology of Spider Venom Neurotoxins. Biochimie 2000, 82, 893–907. [Google Scholar] [CrossRef] [PubMed]
  65. Silva, M.A.; Souza, T.G.; Melo, M.E.G.; Silva, J.M.; Lima, J.R.; Lira, A.F.A.; de Aguiar-Júnior, F.C.A.; Martins, R.D.; Jorge, R.J.B.; Chagas, C.A.; et al. Tityus Stigmurus Venom Causes Genetic Damage in Blood and Testicular Cells and Affects the Number and Morphology of Gametogenic Lineage Cells in Mice. Toxicon 2020, 185, 114–119. [Google Scholar] [CrossRef]
  66. Galvani, N.C.; Vilela, T.C.; Domingos, A.C.; Fagundes, M.Í.; Bosa, L.M.; Della Vechia, I.C.; Scussel, R.; Pereira, M.; Steiner, B.T.; Damiani, A.P.; et al. Genotoxicity Evaluation Induced by Tityus Serrulatus Scorpion Venom in Mice. Toxicon 2017, 140, 132–138. [Google Scholar] [CrossRef]
  67. Das Gupta, S.; Debnath, A.; Saha, A.; Giri, B.; Tripathi, G.; Vedasiromoni, J.R.; Gomes, A.; Gomes, A. Indian Black Scorpion (Heterometrus Bengalensis Koch) Venom Induced Antiproliferative and Apoptogenic Activity against Human Leukemic Cell Lines U937 and K562. Leuk. Res. 2007, 31, 817–825. [Google Scholar] [CrossRef]
  68. da Silva, M.S.; Lopes, P.H.; Elias, M.C.; Tambourgi, D. V Cytotoxic and Genotoxic Effects on Human Keratinocytes Triggered by Sphingomyelinase D from Loxosceles Venom. Arch. Toxicol. 2020, 94, 3563–3577. [Google Scholar] [CrossRef]
  69. Luo, L.; Kamau, P.M.; Lai, R. Bioactive Peptides and Proteins from Wasp Venoms. Biomolecules 2022, 12, 527. [Google Scholar] [CrossRef]
  70. Niidome, T.; Urakawa, M.; Takaji, K.; Matsuo, Y.; Ohmori, N.; Wada, A.; Hirayama, T.; Aoyagi, H. Influence of Lipophilic Groups in Cationic Alpha-Helical Peptides on Their Abilities to Bind with DNA and Deliver Genes into Cells. J. Pept. Res. 1999, 54, 361–367. [Google Scholar] [CrossRef]
  71. Wang, J.; Yan, Z.; Xiao, S.; Wang, B.; Fang, Q.; Schlenke, T.; Ye, G. Characterization of a Cell Death-Inducing Endonuclease-like Venom Protein from the Parasitoid Wasp Pteromalus Puparum (Hymenoptera: Pteromalidae). Pest Manag. Sci. 2021, 77, 224–233. [Google Scholar] [CrossRef]
  72. Khalil, S.R.; Abd-Elhakim, Y.M.; Selim, M.E.; Al-Ayadhi, L.Y. Apitoxin Protects Rat Pups Brain from Propionic Acid-Induced Oxidative Stress: The Expression Pattern of Bcl-2 and Caspase-3 Apoptotic Genes. Neurotoxicology 2015, 49, 121–131. [Google Scholar] [CrossRef] [PubMed]
  73. Gajski, G.; Garaj-Vrhovac, V. Radioprotective Effects of Honeybee Venom (Apis Mellifera) Against 915-MHz Microwave Radiation-Induced DNA Damage in Wistar Rat Lymphocytes: In Vitro Study. Int. J. Toxicol. 2009, 28, 88–98. [Google Scholar] [CrossRef] [PubMed]
  74. Hoshina, M.M.; Marin-Morales, M.A. Anti-Genotoxicity and Anti-Mutagenicity of Apis Mellifera Venom. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2014, 762, 43–48. [Google Scholar] [CrossRef] [PubMed]
  75. Hoshina, M.M.; Santos, L.D.; Palma, M.S.; Marin-Morales, M.A. Cytotoxic, Genotoxic/Antigenotoxic and Mutagenic/Antimutagenic Effects of the Venom of the Wasp Polybia Paulista. Toxicon 2013, 72, 64–70. [Google Scholar] [CrossRef]
  76. Wang, J.; Wang, P.; Zeng, Z.; Lin, C.; Lin, Y.; Cao, D.; Ma, W.; Xu, W.; Xiang, Q.; Luo, L.; et al. Trabectedin in Cancers: Mechanisms and Clinical Applications. Curr. Pharm. Des. 2022, 28, 1949–1965. [Google Scholar] [CrossRef]
  77. D’Incalci, M.; Galmarini, C.M. A Review of Trabectedin (ET-743): A Unique Mechanism of Action. Mol. Cancer Ther. 2010, 9, 2157–2163. [Google Scholar] [CrossRef]
  78. Feuerhahn, S.; Giraudon, C.; Martínez-Díez, M.; Bueren-Calabuig, J.A.; Galmarini, C.M.; Gago, F.; Egly, J.-M. XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids. Chem. Biol. 2011, 18, 988–999. [Google Scholar] [CrossRef]
  79. Bueren-Calabuig, J.A.; Giraudon, C.; Galmarini, C.M.; Egly, J.M.; Gago, F. Temperature-Induced Melting of Double-Stranded DNA in the Absence and Presence of Covalently Bonded Antitumour Drugs: Insight from Molecular Dynamics Simulations. Nucleic Acids Res. 2011, 39, 8248–8257. [Google Scholar] [CrossRef]
  80. Mills, A.; Gago, F. Insight into the Sequence-Specific Elements Leading to Increased DNA Bending and Ligase-Mediated Circularization Propensity by Antitumor Trabectedin. J. Comput. Aided. Mol. Des. 2021, 35, 707–719. [Google Scholar] [CrossRef]
  81. Pellegrino, F.J.; Risso, A.; Corrada, Y.; Gambaro, R.C.; Seoane, A.I. Influence of Dietary Fish Oil Supplementation on DNA Damage in Peripheral Blood Lymphocytes of Nine Healthy Dogs. Vet. Rec. Open 2021, 8, e12. [Google Scholar] [CrossRef]
  82. Giri, B.; Gomes, A.; Debnath, A.; Saha, A.; Biswas, A.K.; Dasgupta, S.C.; Gomes, A. Antiproliferative, Cytotoxic and Apoptogenic Activity of Indian Toad (Bufo Melanostictus, Schneider) Skin Extract on U937 and K562 Cells. Toxicon 2006, 48, 388–400. [Google Scholar] [CrossRef] [PubMed]
  83. Ferraz, C.R.; Arrahman, A.; Xie, C.; Casewell, N.R.; Lewis, R.J.; Kool, J.; Cardoso, F.C. Multifunctional Toxins in Snake Venoms and Therapeutic Implications: From Pain to Hemorrhage and Necrosis. Front. Ecol. Evol. 2019, 7, 218. [Google Scholar] [CrossRef]
  84. Moridikia, A.; Zargan, J.; Sobati, H.; Goodarzi, H.R.; Hajinourmohamadi, A. Anticancer and Antibacterial Effects of Iranian Viper (Vipera Latifii) Venom; an In-Vitro Study. J. Cell. Physiol. 2018, 233, 6790–6797. [Google Scholar] [CrossRef]
  85. Novak Zobiole, N.; Caon, T.; Wildgrube Bertol, J.; de Pereira, C.A.S.; Okubo, B.M.; Moreno, S.E.; Tramontini Gomes de Sousa Cardozo, F. In Vitro and in Vivo Genotoxic Evaluation of Bothrops Moojeni Snake Venom. Pharm. Biol. 2015, 53, 930–934. [Google Scholar] [CrossRef] [PubMed]
  86. Marcussi, S.; Stábeli, R.G.; Santos-Filho, N.A.; Menaldo, D.L.; Silva Pereira, L.L.; Zuliani, J.P.; Calderon, L.A.; da Silva, S.L.; Antunes, L.M.G.; Soares, A.M. Genotoxic Effect of Bothrops Snake Venoms and Isolated Toxins on Human Lymphocyte DNA. Toxicon 2013, 65, 9–14. [Google Scholar] [CrossRef]
  87. Naves, M.P.C.; de Morais, C.R.; de Freitas, V.; Ribeiro, D.L.; Lopes, D.S.; Antunes, L.M.G.; de Melo Rodrigues, V.; de Rezende, A.A.A.; Spanó, M.A. Mutagenic and Genotoxic Activities of Phospholipase A2 Bothropstoxin-I from Bothrops Jararacussu in Drosophila Melanogaster and Human Cell Lines. Int. J. Biol. Macromol. 2021, 182, 1602–1610. [Google Scholar] [CrossRef]
  88. Cardoso Trento, M.V.; de Faria Eleutério, M.W.; Silva Abreu, T.; Andrade Machado, G.H.; Cesar, P.H.S.; Assaid Simão, A.; Marcussi, S. The Protective Effect Exerted by Ascorbic Acid on DNA Fragmentation of Human Leukocytes Induced by Lachesis Muta Muta Venom. J. Cell Biochem 2019, 120, 3520–3528. [Google Scholar] [CrossRef]
  89. Modahl, C.M.; Saviola, A.J.; Mackessy, S.P. Integration of Transcriptomic and Proteomic Approaches for Snake Venom Profiling. Expert Rev. Proteom. 2021, 18, 827–834. [Google Scholar] [CrossRef]
  90. Costa, M.T.; da Silva Goulart, A.; Salgueiro, A.C.F.; da Rosa, H.S.; Perazzo, G.X.; Folmer, V. Cytotoxicity and Inflammation Induced by Philodryas Patagoniensis Venom. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2022, 257, 109356. [Google Scholar] [CrossRef]
  91. Abreu, T.S.; Braga, M.A.; Simão, A.A.; Trento, M.V.C.; de Eleutério, M.W.F.; Silva Pereira, L.L.; Cunha, E.F.F.; Marcussi, S. Mitochondriotropic Action and DNA Protection: Interactions between Phenolic Acids and Enzymes. J. Biochem. Mol. Toxicol. 2020, 34, e22417. [Google Scholar] [CrossRef]
  92. Pan, H.; Soman, N.R.; Schlesinger, P.H.; Lanza, G.M.; Wickline, S.A. Cytolytic Peptide Nanoparticles (‘NanoBees’) for Cancer Therapy. WIREs Nanomed. Nanobiotechnol. 2011, 3, 318–327. [Google Scholar] [CrossRef]
  93. Dabbagh Moghaddam, F.; Akbarzadeh, I.; Marzbankia, E.; Farid, M.; Khaledi, L.; Reihani, A.H.; Javidfar, M.; Mortazavi, P. Delivery of Melittin-Loaded Niosomes for Breast Cancer Treatment: An in Vitro and in Vivo Evaluation of Anti-Cancer Effect. Cancer Nanotechnol. 2021, 12, 14. [Google Scholar] [CrossRef]
  94. Duffy, C.; Sorolla, A.; Wang, E.; Golden, E.; Woodward, E.; Davern, K.; Ho, D.; Johnstone, E.; Pfleger, K.; Redfern, A.; et al. Honeybee Venom and Melittin Suppress Growth Factor Receptor Activation in HER2-Enriched and Triple-Negative Breast Cancer. NPJ Precis. Oncol. 2020, 4, 24. [Google Scholar] [CrossRef]
  95. Choi, K.; Hwang, C.; Gu, S.; Park, M.; Kim, J.; Park, J.; Ahn, Y.; Kim, J.; Song, M.; Song, H.; et al. Cancer Cell Growth Inhibitory Effect of Bee Venom via Increase of Death Receptor 3 Expression and Inactivation of NF-Kappa B in NSCLC Cells. Toxins 2014, 6, 2210–2228. [Google Scholar] [CrossRef]
  96. de Bordon, K.C.F.; Cologna, C.T.; Fornari-Baldo, E.C.; Pinheiro-Júnior, E.L.; Cerni, F.A.; Amorim, F.G.; Anjolette, F.A.P.; Cordeiro, F.A.; Wiezel, G.A.; Cardoso, I.A.; et al. From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery. Front. Pharmacol. 2020, 11, 1132. [Google Scholar] [CrossRef]
  97. Robles-Loaiza, A.A.; Pinos-Tamayo, E.A.; Mendes, B.; Ortega-Pila, J.A.; Proaño-Bolaños, C.; Plisson, F.; Teixeira, C.; Gomes, P.; Almeida, J.R. Traditional and Computational Screening of Non-Toxic Peptides and Approaches to Improving Selectivity. Pharmaceuticals 2022, 15, 323. [Google Scholar] [CrossRef]
  98. Cardoso, M.H.; Orozco, R.Q.; Rezende, S.B.; Rodrigues, G.; Oshiro, K.G.N.; Cândido, E.S.; Franco, O.L. Computer-Aided Design of Antimicrobial Peptides: Are We Generating Effective Drug Candidates? Front. Microbiol. 2020, 10, 3097. [Google Scholar] [CrossRef] [PubMed]
  99. Melo, M.C.R.; Maasch, J.R.M.A.; de la Fuente-Nunez, C. Accelerating Antibiotic Discovery through Artificial Intelligence. Commun. Biol. 2021, 4, 1050. [Google Scholar] [CrossRef]
  100. Torres, M.D.T.; Cao, J.; Franco, O.L.; Lu, T.K.; de la Fuente-Nunez, C. Synthetic Biology and Computer-Based Frameworks for Antimicrobial Peptide Discovery. ACS Nano 2021, 15, 2143–2164. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.